Feed HLN
HL

Haleon HLN NYSE · Healthcare · United Kingdom

$9.07 +0.22% +$0.02

Summary

65 / 100 · Bulios Score

What speaks for it

  • Out of every 100 GBP of revenue, 15 GBP is left as net profit.
  • Earnings per share grew by 16% a year over the last 3 years.

What to watch

  • Revenue grew by only 0.5% a year over the last 3 years.
  • It missed profit estimates 4 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $9.07

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 18.2 29% lower
5-year average P/E 25.5
P/E today 18.2
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 18.2 GBP for 1 GBP of yearly profit. Over the last five years it was 25.5 GBP on average.

Valuation in detail

Is it growing?

Slowly

Revenue (GBP)

Diluted EPS (GBP)

  • Analyst estimate

Revenue grew by 2.2% a year over 5 years. Over the last 3 years it grew by 0.5% a year. For the next fiscal year analysts expect revenue to grow by 2.7%. Earnings per share grew by 16% a year over the last 3 years.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
2.18%
Paid out of profit
40%
Raised in a row
2 years

You receive $0.20 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $10.2 is 12% above today's price. 75% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Respiratory Health brings in 65% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy